Zacks Research Analysts Boost Earnings Estimates for Hologic

Key Points

• Zacks Research has increased its FY2025 earnings estimate for Hologic to $4.22 per share, slightly above the previous forecast of $4.20.
• Hologic reported $1.08 earnings per share for Q3 2023, surpassing analyst estimates and showing a 1.2% year-over-year revenue growth.
• Recent institutional trading saw significant stake increases in Hologic, with the Manufacturers Life Insurance Company raising its holding by 294.3% in the second quarter.

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Equities researchers at Zacks Research lifted their FY2025 EPS estimates for shares of Hologic in a research note issued on Tuesday, August 19th. Zacks Research analyst Team now forecasts that the medical equipment provider will earn $4.22 per share for the year, up from their prior forecast of $4.20. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic's Q2 2026 earnings at $1.05 EPS, Q3 2026 earnings at $1.13 EPS, FY2026 earnings at $4.38 EPS, Q1 2027 earnings at $1.17 EPS, Q3 2027 earnings at $1.20 EPS and FY2027 earnings at $4.77 EPS.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the firm posted $1.06 EPS. The business's revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS.

Several other research firms have also weighed in on HOLX. Stephens reduced their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. UBS Group raised their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. Evercore ISI raised their price objective on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Wall Street Zen upgraded shares of Hologic from a "hold" rating to a "buy" rating in a research report on Friday. Finally, Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and raised their price objective for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $78.00.

Hologic Price Performance

Shares of NASDAQ:HOLX traded up $1.09 during trading hours on Friday, hitting $68.26. 1,545,907 shares of the company's stock traded hands, compared to its average volume of 1,873,376. Hologic has a 52 week low of $51.90 and a 52 week high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company's fifty day simple moving average is $65.90 and its two-hundred day simple moving average is $62.40. The company has a market cap of $15.18 billion, a price-to-earnings ratio of 28.32, a price-to-earnings-growth ratio of 2.48 and a beta of 0.49.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC boosted its holdings in shares of Hologic by 22.3% in the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after buying an additional 335 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Hologic by 116.6% during the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after purchasing an additional 5,172 shares during the period. Brevan Howard Capital Management LP boosted its holdings in shares of Hologic by 85.5% during the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock worth $1,401,000 after purchasing an additional 8,960 shares during the period. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Hologic by 1.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock worth $1,980,000 after purchasing an additional 528 shares during the period. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Hologic by 4.5% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 17,945 shares of the medical equipment provider's stock worth $1,108,000 after purchasing an additional 767 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.